Merck & Co Inc (NYSE:MRK) is making significant progress in its pipeline, with 20 potential new growth drivers, many with blockbuster potential. The Animal Health business delivered strong ...

Welcome to the Merck & Company Q4 sales and earnings conference call. [Operator instructions] This call is being recorded.

However, the reality is anyone with lungs can get lung cancer,” 6 said Beverley, a retired wealth management professional who was diagnosed with stage 4 non-small ... Canada, Merck markets a broad ...

Merck (MRK) stock was mangled today after the pharmaceutical and vaccine company released its guidance for 2025. The company expects adjusted ...

Merck (MRK) shares drop 8% premarket as 2025 outlook falls short of Wall Street estimates, despite beating Q4 expectations ...

Reports Q4 revenue $15.6B, consensus $15.51B. “We delivered strong growth in 2024, reflecting demand for our innovative portfolio, including ...

Biopharmaceutical company Merck & Co., Inc. (MRK) reported Tuesday a net profit for the fourth quarter compared to a loss last year, ...

the successful launch of WINREVAIR and strong performance of our Animal Health business," said Robert Davis, chairman and chief executive officer, Merck. Also Read: RJK Jr.'s Involvement In Merck ...